Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC raised its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 287.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 702,239 shares of the company's stock after purchasing an additional 520,859 shares during the period. Gilder Gagnon Howe & Co. LLC owned 1.11% of Evolus worth $7,753,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in EOLS. KBC Group NV acquired a new position in Evolus in the 4th quarter worth about $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus in the fourth quarter valued at approximately $106,000. Quantbot Technologies LP purchased a new position in shares of Evolus during the fourth quarter worth approximately $118,000. Finally, Tradition Wealth Management LLC grew its stake in shares of Evolus by 18.2% in the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after purchasing an additional 2,000 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on EOLS. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Finally, BTIG Research started coverage on Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $23.75.

Insider Transactions at Evolus

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Moatazedi sold 6,251 shares of the stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 in the last quarter. Insiders own 6.10% of the company's stock.

Evolus Trading Up 1.4 %

NASDAQ EOLS traded up $0.17 during trading hours on Friday, hitting $11.97. 468,863 shares of the company's stock were exchanged, compared to its average volume of 666,634. The firm has a market cap of $760.88 million, a price-to-earnings ratio of -13.17 and a beta of 0.97. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The stock has a 50-day simple moving average of $12.02 and a 200 day simple moving average of $12.80. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.